
Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year.
U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase when excluding foreign exchange impacts (Ex-FX).